Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179062 · ClinicalTrials.gov registry record · NA
Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 300
- Enrollment target
NCT00179062 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 300 participants.
The verdict
NCT00179062, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
Study Summary
This twelve month, open-label study considers the effect of Risperdal (risperidone) versus Zyprexa (olanzapine) on weight gain, physical health, and outcome in a population of those diagnosed with schizophrenia, schizoaffective disorder, major depression or bipolar disorder with psychotic features. This study evaluates symptom response as well as general health indicators such as body mass index, glucose, prolactin, and cholesterol levels at baseline, month (M)1, M3, M6 and M12.
Interventions
- DRUG olanzapine versus risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2000-02 |
| Est. Completion | 2007-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179062
The ClinicalTrials.gov registry entry for NCT00179062 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which olanzapine versus risperidone is the first listed.
NCT00179062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179062 about?
NCT00179062 is a clinical study titled "Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder". This twelve month, open-label study considers the effect of Risperdal (risperidone) versus Zyprexa (olanzapine) on weight gain, physical health, and outcome in a population of those diagnosed with schizophrenia, schizoaffective disorder, major depression or bipolar disorder with psychotic features. ...
What is the current status of trial NCT00179062?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2000-02. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00179062?
The interventions under investigation include: olanzapine versus risperidone (DRUG).
Who is sponsoring clinical trial NCT00179062?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.